US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Bulletin from the extraordinary general meeting on 7 January 2025 in PEPTONIC medical AB

The extraordinary general meeting of PEPTONIC medical AB, reg. no. 556776-3064 (the “Company”), was held today on 7 January 2025. The meeting resolved, with the required majority, in accordance with all proposed resolutions. Below is a summary of the main resolutions that were passed.Election of a new board member                    The meeting resolved to elect Jakob Ericsson as a new ordinary board member, for the period until the end of the 2025 annual general meeting. The board of directors thus consists of Anders Blom, Daniel Rudeklint, Tarek Shoeb and Jacob Eriksson. Jacob

NOTICE OF EXTRAORDINARY GENERAL MEETING IN PEPTONIC MEDICAL AB

N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the extraordinary general meeting in PEPTONIC medical AB, and in case of any discrepancies between the Swedish and the English translation, the Swedish text shall prevail. The shareholders of PEPTONIC medical AB, reg. no. 556776-3064 (the "Company"), are hereby convened to an extraordinary general meeting on 7 January 2025 at 10.00 a.m. at Eversheds Sutherland Advokatbyrå's premises at Sveavägen 20 in Stockholm. Registration begins at 09.45.RIGHT TO PARTICIPATE and NOTICE OF PARTICIPATION

The board of Peptonic resolves, subject to the approval a subsequent general meeting, on a rights issue of units of approximately SEK 26.5 million

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW. Peptonic medical AB ("Peptonic” or the "Company") announces that the board today, subject to approval of a subsequent general meeting, has decided to carry out an issue of units with preferential rights for existing shareholders of approximately SEK 26.5

Peptonic receives approximately SEK 49.9 thousand through warrants of series TO5

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW. PEPTONIC medical AB ("Peptonic" or the "Company") today announces the outcome of the exercise of warrants of series TO5 (”TO5”). In total, 3,839,942 TO5 were exercised, corresponding to approximately 0.18 percent of the total number of outstanding TO5, for

Peptonic Medical publishes an operational update

Today, Peptonic Medical AB ("Peptonic") publishes an operational update outlining the strategic actions and initiatives implemented and planned for the year. These efforts are expected to position the company to achieve positive cash flow in the second half of 2025.Expansion in the USA. After more than six months of preparation, including the development of a new e-commerce platform, the creation of sales and marketing strategies, and initiating influencer partnerships, Peptonic is set to launch an extensive digital marketing campaign for VagiVital in the U.S. in November. This campaign

The last day of trading with the warrants of series TO5 in PEPTONIC medical AB is today, November 15, 2024

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW. Today, November 15, 2024, is the last day of trading with the warrants of series TO5 (“TO5”) in PEPTONIC medical AB (“Peptonic” or the “Company”). The exercise period for TO5 runs up to and including November 20, 2024. Each TO5 gives the owner the right to

Peptonic Medical AB closes its Israeli subsidiary

Peptonic Medical AB ("Peptonic") today announces its decision to discontinue its Israeli subsidiary, a contract manufacturing organization (CMO) specializing in self-diagnostic tests. The decision will result in significant cost savings. Acquired in 2021 alongside the U.S.-based company Common Sense Marketing Inc. ("Common Sense"), the Israeli manufacturing organization has encountered profitability challenges and increasing operational complexities in Israel. Going forward, Peptonic plans to partner with an external contract manufacturer, while retaining Common Sense as a strategic asset to

The exercise period for subscription of shares through exercise of warrants of series TO5 begins today

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW. Today, 6 November 2024, the exercise period for warrants of series TO5 (“TO5”) in PEPTONIC medical AB ("Peptonic" or “the Company”) begins. The exercise period runs from and including November 6, 2024, until and including November 20, 2024. Each TO5 entitles

Peptonic Medical strengthens U.S. market presence with full-scale launch of VagiVital

Peptonic Medical AB (publ) ("Peptonic") is taking a crucial step to establish its VagiVital brand in the U.S. market and drive sales growth of its intimate self-care products. This initiative marks a significant milestone for Peptonic, as the company now assumes full control over brand development, marketing, and sales in the U.S. for the first time. Until now, Peptonic's products have primarily been sold through partners under private labels. With this strategic initiative, Peptonic is positioning itself for a dynamic new phase of growth in the world’s largest healthcare market.Over the

Peptonic Medical launches proprietary lubricant that combines pleasure and care

Peptonic Medical (publ) ("Peptonic") is expanding its portfolio of clinically proven intimate self-care products with the launch of VagiVital Active Glide, a water-based lubricant specifically designed to enhance intimate experiences while providing deep hydration. This strategic addition to Peptonic’s growing product portfolio addresses the rising demand for lubricants that combine pleasure with care. In 2022, the global market for personal lubricants was valued at approximately USD 1.2 billion and is expected to experience continued strong growth in the coming years.The personal lubricant

Peptonic announces the last day of trading in BTU and the first day of trading in warrants of series TO 5

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. PEPTONIC medical AB ("Peptonic” or the "Company") announces that the rights issue which the board of directors resolved on April 16, 2024, and was approved at the annual general meeting

Peptonic Medical AB Granted Patent in Australia: Vernivia Secures Exclusivity Until 2038

Peptonic Medical AB (publ) ("Peptonic") has received notification that the Australian patent office has granted the FOAM II patent. This patent provides broad protection for Peptonic's self-care product Vernivia, an over-the-counter and antibiotic-free treatment for bacterial vaginosis, as well as the company's mousse-based drug delivery technology Venerol. The patent extends until May 2038, ensuring Vernivia's market exclusivity.Bacterial vaginosis is very common, especially among women of reproductive age, affecting approximately one in three women. Vernivia is the first clinically proven

Peptonic announces outcome in the rights issue and the directed issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. PEPTONIC medical AB ("Peptonic” or the "Company") has completed the rights issue of units, consisting of shares and warrants of series TO5, which the board of directors resolved on April

Peptonic Medical provides an operational update after the first 120 days with new CEO

Peptonic Medical AB ("Peptonic") today presents an operational update highlighting the strategic measures implemented during Anna Linton's first 120 days as CEO. These efforts, aimed at achieving profitability, combine initiatives for increased sales and cost efficiency.Initiatives for Increased Sales Strategic shift in focus: The company has more clearly shifted its focus towards sales growth. Resources are now more heavily allocated to sales and marketing activities for the existing portfolio of intimate self-care products, while fewer resources are dedicated to the development of

Last day of trading with the unit rights in Peptonic

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Today, June 7, 2024, is the last day of trading with the unit rights that were issued in conjunction with PEPTONIC medical AB  ("Peptonic” or the "Company") rights issue of units

Peptonic Medical AB granted patent in Europe for relief of provoked vulvodynia in women. Product ready for launch.

Peptonic Medical AB (publ) ("Peptonic") announces that the European Patent Office ("EPO") has granted a patent for the relief of provoked vulvodynia (previously referred to as vestibulitis), effective until April 2041. VagiVital Intimate Calming Gel, the company's proprietary product designed to alleviate the discomfort associated with vulvodynia, will be launched later this year. The product will also be introduced to existing and new international partners for broad distribution.VagiVital Intimate Calming Gel provides immediate soothing and moisturizing effects for vulvodynia and relieves

The subscription period in Peptonic’s rights issue of units starts today

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATIONOF THIS PRESS RELEASE WOULD BE UNLAWFULOR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Today, 28 May, 2024, the subscription period begins in PEPTONIC medical AB (publ) ("Peptonic” or the "Company") rights issue of units consisting of shares and warrants (the "Rights Issue"),

Peptonic publishes prospectus in connection with rights issue of units

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATIONOF THIS PRESS RELEASE WOULD BE UNLAWFULOR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. PEPTONIC medical AB (publ) ("Peptonic” or the "Company") has prepared an EU growth prospectus (the "Prospectus") for the forthcoming issue of units consisting of shares and warrants with

Peptonic Medical AB Announces Organizational Changes

Peptonic Medical AB (publ) ("Peptonic") announces today changes within its organization. Global Business Director, Erik Sundquist, and Senior Advisor, Dan Markusson, will be leaving their positions in the company.During his time at Peptonic, Erik Sundquist has played a key role in strengthening the company's market position and implementing important business strategies. Erik has decided to focus on other professional projects. Dan Markusson, who has held several significant positions within the company, will be leaving Peptonic in mid-June. "We are grateful for Erik's and Dan's efforts

The board of Peptonic has decided to carry out a directed issue of units consisting of shares and warrants of series TO5

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW. Peptonic medical AB (publ) ("Peptonic” or the "Company") announces that the board today, with authorization from the annual general meeting on May 24, 2023, has decided to offer all holders of interim shares to participate in a directed issue of a total of 3,

Jenni Björnulfson appointed as new CFO of Peptonic Medical

Peptonic Medical AB (publ) ("Peptonic") announces the appointment of Jenni Björnulfson as the company's new Chief Financial Officer (CFO). Jenni will assume the position on September 1, 2024, replacing Albert Lindgren. During the transition period until Jenni assumes office, Daniel Rudeklint will serve as Acting CFO.Expressing enthusiasm for the appointment, Peptonic’s CEO looks forward to welcoming Jenni to the company. "Jenni brings with her a solid experience in finance and possesses a profound understanding of both public companies and the life science industry. I am confident that her

Warrants of series TO4 were subscribed to approximately 1.80 percent and Peptonic receives approximately SEK 0.1 million

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW. PEPTONIC medical AB ("Peptonic" or the "Company") today announces the outcome of the exercise of warrants of series TO4 (the “Warrants”). In total, 3,538,820 Warrants were exercised, corresponding to approximately 1.80 percent of the total number of outstanding

The last day of trading with the warrants of series TO4 in PEPTONIC medical AB is today, April 26, 2024

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW. Today, April 26, 2024, is the last day of trading with the warrants of series TO4 (“Warrants”) in PEPTONIC medical AB (“Peptonic” or the “Company”). The exercise period for the Warrants runs up to and including May 1, 2024. Each Warrant gives the owner the

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe